Abstract Details

Title Is Intravenous Immunoglobulin More Cost Effective Than Plasmapheresis in the Treatment of Pediatric Guillain Barre Syndrome. Data from Kids' Inpatient Database (KID) 1997-2009

Topic Child Neurology/Developmental Neurobiology

Presentation(s) P03 - (-)

Poster/Presentation
Number 003

Objective

Background BACKGROUND: Over the past decade, IVIg have been more extensively used as an alternative to plasmapheresis to treats GBS.

Design/Methods DESIGN/METHODS: We analyzed the Kid's Inpatient Database (KID) for age, race, length of stay, disposition/outcome, and cost of stay for pediatric patients hospitalized with GBS between 1997 and 2009. We compared these variables when patients were treated with IVIg versus plasmapheresis.

Results RESULTS: Among 368, 134, 118, 174, 244 pediatric patients admitted to hospitals for GBS on 1997, 2000, 2003, 2006, 2009 respectively, 333/35, 88/46, 85/33, 139/35, 214/30 were treated with IVIg/plasmapheresis respectively. The average age of patients treated with IVIG was significantly lower than the average age of patients treated with plasmapheresis (P<001). The mean length of stay was significantly longer in patients treated with plasmapheresis in all time periods: for IVIG patients the average length of stay varied between 6.46 and 10 days, whereas for plasmapheresis, it varied between 15.52 and 21.73 days (p<0.001). Of the patients treated with IVIg, 66.4% to 77.6% were discharged home, whereas 28.6% to 40% of patients were discharged home in the plasmapheresis group. The mean hospitalization charges was significantly higher in the plasmapheresis group compared to IVIG group in all time periods. It varied from $ 56,072 in 1997 and $235,712 in 2009 in the plasmapheresis group. In the IVIg group the mean hospitalization charges varied between $30,010 in 1997 and $ 88,621 in 2009.

Conclusions CONCLUSIONS: The mean hospitalization charges and mean hospitalization length of stay of pediatric patients with GBS treated with plasmapheresis were higher than in group of patients treated with IVIg in 1997 to 2009 time periods.

Authors/Disclosures
Rania A. Elenein, MD (Jefferson Health NJ) PRESENTER	Dr. Elenein has nothing to disclose.
Wenzhuan He, MD (UPMC Susquehanna Neurology)	Dr. He has nothing to disclose.
Nizar Souayah, MD, FAAN (NJMS)	Dr. Souayah has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Takeda. Dr. Souayah has received publishing royalties from a publication relating to health care.
Gavin Giovannoni, MD (QMUL)	Dr. Giovannoni has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Biogen. Dr. Giovannoni has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Sanofi. Dr. Giovannoni has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Merck KGaA. Dr. Giovannoni has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Roche-Genentech. Dr. Giovannoni has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Moderna. Dr. Giovannoni has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Sandoz. Dr. Giovannoni has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Astoria Biologica. Dr. Giovannoni has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Zenas. Dr. Giovannoni has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Biogen. Dr. Giovannoni has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Roche. Dr. Giovannoni has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Sanofi. Dr. Giovannoni has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for Medscape.

��ɫ��

��ɫ��